Market Cap 17.98M
Revenue (ttm) 0.00
Net Income (ttm) -27.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 273,100
Avg Vol 237,342
Day's Range N/A - N/A
Shares Out 2.20M
Stochastic %K 26%
Beta 0.27
Analysts Strong Sell
Price Target $61.67

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 702 9600
Address:
545 Concord Avenue, Suite 210, Cambridge, United States
Joefreeagent
Joefreeagent Jan. 14 at 9:42 PM
$MTVA I am out. Nothing but an endless scam.
1 · Reply
TraderRapp
TraderRapp Jan. 14 at 9:20 PM
$MTVA no way they fund this at $8.15 strike warrants. They are struggling to find funding after a second S-1 offering.
1 · Reply
Vutch
Vutch Jan. 14 at 9:14 PM
$MTVA https://themedicinemaker.com/issues/2026/articles/january/a-turning-point-in-mash/
0 · Reply
Moe_cash
Moe_cash Jan. 14 at 8:55 PM
$MTVA some people here are delusional. Long hold until what? It R/S again and again? lol
0 · Reply
Ren_Stimpy
Ren_Stimpy Jan. 14 at 8:41 PM
$MTVA https://www.sec.gov/Archives/edgar/data/1638287/000110465926002930/tm2528002-13_s1a.htm
0 · Reply
Ren_Stimpy
Ren_Stimpy Jan. 14 at 8:39 PM
$MTVA has major share delusion coming according to their latest sec filing.
0 · Reply
elitechrisvp
elitechrisvp Jan. 14 at 8:31 PM
$MTVA 🤔
0 · Reply
Winnning
Winnning Jan. 14 at 8:30 PM
$MTVA why the drop?
1 · Reply
Kinderla
Kinderla Jan. 14 at 5:41 PM
$MTVA I’m with you TraderRapp. The 48mg trial went well and this thing is near a 52 week low. I believe it’s a bargain
2 · Reply
Moe_cash
Moe_cash Jan. 14 at 4:57 PM
$MTVA must have meant .40 on that upgrade.
0 · Reply
Latest News on MTVA
MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Dec 2, 2025, 8:45 AM EST - 6 weeks ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split


MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 26, 2025, 8:31 AM EDT - 5 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences


Joefreeagent
Joefreeagent Jan. 14 at 9:42 PM
$MTVA I am out. Nothing but an endless scam.
1 · Reply
TraderRapp
TraderRapp Jan. 14 at 9:20 PM
$MTVA no way they fund this at $8.15 strike warrants. They are struggling to find funding after a second S-1 offering.
1 · Reply
Vutch
Vutch Jan. 14 at 9:14 PM
$MTVA https://themedicinemaker.com/issues/2026/articles/january/a-turning-point-in-mash/
0 · Reply
Moe_cash
Moe_cash Jan. 14 at 8:55 PM
$MTVA some people here are delusional. Long hold until what? It R/S again and again? lol
0 · Reply
Ren_Stimpy
Ren_Stimpy Jan. 14 at 8:41 PM
$MTVA https://www.sec.gov/Archives/edgar/data/1638287/000110465926002930/tm2528002-13_s1a.htm
0 · Reply
Ren_Stimpy
Ren_Stimpy Jan. 14 at 8:39 PM
$MTVA has major share delusion coming according to their latest sec filing.
0 · Reply
elitechrisvp
elitechrisvp Jan. 14 at 8:31 PM
$MTVA 🤔
0 · Reply
Winnning
Winnning Jan. 14 at 8:30 PM
$MTVA why the drop?
1 · Reply
Kinderla
Kinderla Jan. 14 at 5:41 PM
$MTVA I’m with you TraderRapp. The 48mg trial went well and this thing is near a 52 week low. I believe it’s a bargain
2 · Reply
Moe_cash
Moe_cash Jan. 14 at 4:57 PM
$MTVA must have meant .40 on that upgrade.
0 · Reply
Kertzi
Kertzi Jan. 14 at 4:41 PM
0 · Reply
TraderRapp
TraderRapp Jan. 14 at 4:39 PM
$MTVA ok, I'll bite some here again...still working on financing the phase1 trial, no shares available
0 · Reply
Kertzi
Kertzi Jan. 13 at 4:19 PM
$MTVA I have told the truth about this "company" many, many, many times, and these delusional pumpers have trashed my posts just as many times. Where are you now, clowns?!
0 · Reply
TraderRapp
TraderRapp Jan. 6 at 11:00 PM
$MTVA So looks like they running a phase1- part 3 now. With even higher dose and titrated. Of course diluting offering/warrants to find it. Sigh. They strategically referred to DA-1726 as a “metabolic disease” instead of obesity. Despite its weight loss being better than any other GLP-1/GCRc drug and still not done feasting doses and titrations. So now gotta wait for EOY results and phase 2 in 2027. Might still be a excellent longterm investment if they show part 3 robust weight loss. Otherwise this is rinse and repeat for another year.
2 · Reply
TraderRapp
TraderRapp Jan. 6 at 9:00 PM
$MTVA "HC Wainwright & Co. analyst Andrew S. Fein maintains MetaVia(MTVA) with a Buy and raises the price target from $12 to $40."
0 · Reply
jabroni1111
jabroni1111 Jan. 6 at 6:17 PM
$MTVA decent upgrade though
0 · Reply
Kertzi
Kertzi Jan. 6 at 4:32 AM
$MTVA Serious question: Beyond PR headlines, what is actually left here? No breakthrough data, no competitive edge, no visibility on funding without massive dilution. Is 2026 the end of the road for NeuroScam?
0 · Reply
lovestockstwits
lovestockstwits Jan. 5 at 10:26 PM
$MTVA scam shix
0 · Reply
TwongStocks
TwongStocks Jan. 5 at 9:22 PM
One month post-RS recap $IMG 1:20 RS Dec 5, closed $2.52 Reached $2.696 the day after the RS, but traded below that since. Today closed $1.17, down 53.57% from RS close $MTVA 1:11 RS Dec 5, closed $8.1819 Reached $13.42 the day after the RS. If you bought at the low of $7.22 day of the RS, it would have been a 86% swing. Today closed $8.73, up 6.70% from RS close. $TGL 1:20 RS Dec 5, closed $25.44 Reached $58 the day after the RS. If you bought at the low of $6.82 day of the RS, it would have been a 750% swing. Today closed $6.92, down 72.80% from RS close
0 · Reply
BioTuesdays
BioTuesdays Jan. 5 at 8:32 PM
$MTVA has announced positive, statistically significant results from the eight-week, non-titrated, 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), for the treatment of obesity https://biotuesdays.com/2026/01/05/metavia-reports-positive-results-from-phase-1b-trial-of-da-1726-in-metabolic-disease/
0 · Reply
jabroni1111
jabroni1111 Jan. 5 at 8:18 PM
$MTVA hmmmm was hoping for this to blast after update
0 · Reply
JohnTrack
JohnTrack Jan. 5 at 6:54 PM
$MTVA Positive Results from Its Phase 1b Clinical Trial of DA-1726 https://www.rapidticker.com/news/mtva-sec-filing-7a9267
0 · Reply